Literature DB >> 24019330

Resistance emerges to second-generation antiandrogens in prostate cancer.

William G Nelson1, Srinivasan Yegnasubramanian.   

Abstract

The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24019330      PMCID： PMC3800038          DOI： 10.1158/2159-8290.CD-13-0405

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

1.  The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.

Authors:  F S Leach; A Velasco; J T Hsieh; A I Sagalowsky; J D McConnell
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis.

Authors:  T D Tlsty; B H Margolin; K Lum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 3.  Common gene rearrangements in prostate cancer.

Authors:  Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

Review 4.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

5.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 7.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

8.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Authors:  Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu
Journal:  Cancer Discov       Date:  2013-07-10       Impact factor: 39.397

9.  Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Authors:  Michael C Haffner; Martin J Aryee; Antoun Toubaji; David M Esopi; Roula Albadine; Bora Gurel; William B Isaacs; G Steven Bova; Wennuan Liu; Jianfeng Xu; Alan K Meeker; George Netto; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

10.  Overcoming mutation-based resistance to antiandrogens with rational drug design.

Authors:  Minna D Balbas; Michael J Evans; David J Hosfield; John Wongvipat; Vivek K Arora; Philip A Watson; Yu Chen; Geoffrey L Greene; Yang Shen; Charles L Sawyers
Journal:  Elife       Date:  2013-04-09       Impact factor: 8.140
View more
  18 in total

1.  Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Authors:  Elena V Fernandez; Kelie M Reece; Ariel M Ley; Sarah M Troutman; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Mol Pharmacol       Date:  2015-03-31       Impact factor: 4.436

2.  miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

3.  Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Authors:  Xin Chen; Qiuhui Li; Xin Liu; Can Liu; Ruifang Liu; Kiera Rycaj; Dingxiao Zhang; Bigang Liu; Collene Jeter; Tammy Calhoun-Davis; Kevin Lin; Yue Lu; Hsueh-Ping Chao; Jianjun Shen; Dean G Tang
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

Review 4.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

5.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Authors:  Anu-Maarit Moilanen; Reetta Riikonen; Riikka Oksala; Laura Ravanti; Eija Aho; Gerd Wohlfahrt; Pirjo S Nykänen; Olli P Törmäkangas; Jorma J Palvimo; Pekka J Kallio
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

6.  Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data.

Authors:  Yumin Wang; Tingting Qin; Wangqiang Hu; Binghua Chen; Meijie Dai; Gang Xu
Journal:  Genes (Basel)       Date:  2018-01-11       Impact factor: 4.096

Review 7.  Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

Authors:  David T Hoang; Kenneth A Iczkowski; Deepak Kilari; William See; Marja T Nevalainen
Journal:  Oncotarget       Date:  2017-01-10

Review 8.  Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?

Authors:  Hannelore V Heemers
Journal:  Int J Biol Sci       Date:  2014-06-01       Impact factor: 6.580

9.  Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.

Authors:  Kenneth J Pienta; Guneet Walia; Jonathan W Simons; Howard R Soule
Journal:  Prostate       Date:  2014-02       Impact factor: 4.104

10.  Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

Authors:  Daniel O'Neill; Dominic Jones; Mark Wade; James Grey; Sirintra Nakjang; Wenrui Guo; David Cork; Barry R Davies; Steve R Wedge; Craig N Robson; Luke Gaughan
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.